
Anthrax Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Anthrax Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.
Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 16 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.
Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.
Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 16 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.
Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Aphios Corp
Biologics Resources LLC
BlueWillow Biologics Inc
China Biologic Products Holdings Inc
Crestone Inc
Dynavax Technologies Corp
Emergent BioSolutions Inc
GC Pharma
Greffex Inc
Hawaii Biotech Inc
iBio Inc
Innovative Biologics Inc
Integrated BioTherapeutics Inc
iNtRON Biotechnology Inc
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Paratek Pharmaceuticals Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Vast Therapeutics Inc
Venomyx Inc
VLP Biotech Inc
Companies Mentioned
Aphios Corp
Biologics Resources LLC
BlueWillow Biologics Inc
China Biologic Products Holdings Inc
Crestone Inc
Dynavax Technologies Corp
Emergent BioSolutions Inc
GC Pharma
Greffex Inc
Hawaii Biotech Inc
iBio Inc
Innovative Biologics Inc
Integrated BioTherapeutics Inc
iNtRON Biotechnology Inc
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Paratek Pharmaceuticals Inc
Protein Potential LLC
ProThera Biologics Inc
Soligenix Inc
Vast Therapeutics Inc
Venomyx Inc
VLP Biotech Inc
Table of Contents
82 Pages
- Introduction
- Global Markets Direct Report Coverage
- Anthrax - Overview
- Anthrax - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Anthrax - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anthrax - Companies Involved in Therapeutics Development
- Aphios Corp
- Biologics Resources LLC
- BlueWillow Biologics Inc
- China Biologic Products Holdings Inc
- Crestone Inc
- Dynavax Technologies Corp
- Emergent BioSolutions Inc
- GC Pharma
- Greffex Inc
- Hawaii Biotech Inc
- iBio Inc
- Innovative Biologics Inc
- Integrated BioTherapeutics Inc
- iNtRON Biotechnology Inc
- NovoBiotic Pharmaceuticals LLC
- Opal Biosciences Ltd
- Paratek Pharmaceuticals Inc
- Protein Potential LLC
- ProThera Biologics Inc
- Soligenix Inc
- Vast Therapeutics Inc
- Venomyx Inc
- VLP Biotech Inc
- Anthrax - Drug Profiles
- (anthrax + plague) (multivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- anthrax (virus like particles, bivalent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- anthrax + plague vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- anthrax [strain Alls/Gifford] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- anthrax vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- anthrax vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Antibody for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- AV-7909 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BAL-200 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BDM-I - Drug Profile
- Product Description
- Mechanism Of Action
- BIOC-51 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BW-1010 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CRS-0540 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DV-230F - Drug Profile
- Product Description
- Mechanism Of Action
- GC-1109 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GREANX - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Marinus - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- omadacycline tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Protein to Inhibit Furin for Anthrax and Bacterial Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Proteins for Anthrax and Methicillin Resistant Staphylococcus Aureus (MRSA) Infections - Drug Profile
- Product Description
- Mechanism Of Action
- RiVax + SGX-204 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rPA-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Inhibit Lethal Factor for Anthrax - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Bacterial Infections and Bone Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- Teixobactin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Anthrax - Dormant Projects
- Anthrax - Discontinued Products
- Anthrax - Product Development Milestones
- Featured News & Press Releases
- Oct 26, 2021: BlueWillow Biologics to present during BARDA Industry Day 2021
- Sep 27, 2021: Paratek Pharmaceuticals announces additional funding under the BARDA contract to advance the development of NUZYRA (omadacycline) for post-exposure prophylaxis (PEP) and treatment of pulmonary anthrax
- Aug 24, 2021: BlueWillow Biologics announces positive interim results from phase 1 trial of intranasal anthrax vaccine
- Jun 29, 2021: Paratek Pharmaceuticals announces first BARDA project Bioshield procurement of NUZYRA (omadacycline) valued at ~$38 million
- Jul 13, 2020: Emergent BioSolutions received a contract modification from the Office of the Assistant Secretary
- Mar 10, 2020: Paratek Pharmaceuticals announces the submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)
- Dec 18, 2019: Paratek awarded BARDA project BioShield contract for NUZYRA
- Oct 23, 2019: BlueWillow receives FDA clearance to begin phase 1 study of its intranasal Anthrax Vaccine
- May 29, 2019: BlueWillow Biologics announces issuance of intranasal Anthrax Vaccine patent
- May 15, 2019: Emergent BioSolutions prepares for initial shipments of AV7909 anthrax vaccine candidate into the strategic national stockpile
- Mar 20, 2019: Emergent BioSolutions launches Phase III trial of anthrax vaccine
- Jan 09, 2019: Vast Therapeutics Announces Results Showing Ability to Eradicate Anthrax
- Dec 28, 2018: Emergent BioSolutions announces submission to FDA of application covering emergency use authorization for NuThrax
- Jun 19, 2017: NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine
- Jun 22, 2016: U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of NuThrax Vaccines
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Anthrax, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Anthrax - Pipeline by Aphios Corp, 2022
- Anthrax - Pipeline by Biologics Resources LLC, 2022
- Anthrax - Pipeline by BlueWillow Biologics Inc, 2022
- Anthrax - Pipeline by China Biologic Products Holdings Inc, 2022
- Anthrax - Pipeline by Crestone Inc, 2022
- Anthrax - Pipeline by Dynavax Technologies Corp, 2022
- Anthrax - Pipeline by Emergent BioSolutions Inc, 2022
- Anthrax - Pipeline by GC Pharma, 2022
- Anthrax - Pipeline by Greffex Inc, 2022
- Anthrax - Pipeline by Hawaii Biotech Inc, 2022
- Anthrax - Pipeline by iBio Inc, 2022
- Anthrax - Pipeline by Innovative Biologics Inc, 2022
- Anthrax - Pipeline by Integrated BioTherapeutics Inc, 2022
- Anthrax - Pipeline by iNtRON Biotechnology Inc, 2022
- Anthrax - Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
- Anthrax - Pipeline by Opal Biosciences Ltd, 2022
- Anthrax - Pipeline by Paratek Pharmaceuticals Inc, 2022
- Anthrax - Pipeline by Protein Potential LLC, 2022
- Anthrax - Pipeline by ProThera Biologics Inc, 2022
- Anthrax - Pipeline by Soligenix Inc, 2022
- Anthrax - Pipeline by Vast Therapeutics Inc, 2022
- Anthrax - Pipeline by Venomyx Inc, 2022
- Anthrax - Pipeline by VLP Biotech Inc, 2022
- Anthrax - Dormant Projects, 2022
- Anthrax - Dormant Projects, 2022 (Contd..1)
- Anthrax - Dormant Projects, 2022 (Contd..2)
- Anthrax - Dormant Projects, 2022 (Contd..3)
- Anthrax - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Anthrax, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.